Suppression of HIV Replication and Prevention/Treatment of HIV-Associated Dementia by Minocycline

This invention describes the addition of a tetracycline derviative to existing combinations of antiretroviral drugs for treatment of HIV-infected individuals. JHU researchers have determined that the tetracycline derivative, which is a potent anti-inflammatory and neuroprotective drug, also inhibits SIV replication in macrophages, the major target cell for HIV/SIV replication in the brain. This invention provides for the use of a tetracycline derviative in combination with currently existing antiretroviral therapeutics to both suppress HIV replication in the periphery and in the brain and to prevent or decrease the neurological manifestations of HIV infection. Description (Set) Proposed Use (Set) A. To use this drug to inhibit virus replication, and particularly HIV replication. For decades, a tetracycline derviative has been used as an antibacterial agent. It is available in a generic form and has been demonstrated to be well-tolerated over long periods of use. Studies in our lab indicate that this compound is effective in suppressing SIV replication in macrophages and microglial cells, the major targets for virus replication in the brain. B. To use this drug as a neuroprotective agent in patients with HIV infection. In recent years, studies have demonstrated this compound's neuroprotective effects in animal models of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Hunington's disease and ischemic/traumatic brain injury. Clinical studies have demonstrated this compound's anti-inflammatory properties to be useful in the treatment of rheumatoid arthritis and osteoarthritis.

Inventor(s): Zink, Mary

Type of Offer: Licensing



« More Pharmaceutical Patents
« More Medical Patents

---